Microbiome
·
2025
·Vol. 13
·期 1
·250
·
IF 12.7
Zhao Feng,Wang Jiao,Liang Weijuan,Sun Fanwei,Liu Zhaoyi,Wu Yuehua,Khan Ahmad,Wang Chunsong,Zhou Ruiqi,Feng Huaili,You Ting,Duan Xinhao,Zhang Hongyang,Qiu Jingfu,Chen Chengzhi
Background The contribution of dietary interventions, particularly lysine-restricted diets (LRD), to ameliorating obesity-associated anxiety-like behaviors remains elusive, with limited evidence clarifying microbiota-metabolite-brain axis pathways involved. Results Herein, our results demonstrated that LRD attenuated high-fat diet (HFD)-induced anxiety-like behaviors while concomitantly reducing body weight and improving glucose metabolism. Furthermore, LRD significantly remodeled gut microbiota composition, most notably enriching the abundance of Oscillibacter. We then screened and identified that both viable and encapsulated Oscillibacter ruminantium alleviated obesity- and chronic restraint stress-induced anxiety-like behaviors, with microencapsulated formulations conferring superior anxiolytic efficacy. Notably, the obtained data revealed that LRD reversed HFD-induced the depletion of tryptophol, which was established as the metabolite of Oscillibacter ruminantium, and LRD could also alleviate the intestinal barrier impairment caused by HFD. Mechanistic results further demonstrated that tryptophol supplementation ameliorated HFD-driven anxiety-like phenotypes by inhibiting FTO-mediated reader protein IGF2BP1, and thereby reducing m⁶A modification of Lgr6 mRNA. Conclusion LRD attenuates obesity-associated anxiety-like behaviors by enriching Oscillibacter ruminantium and modulating tryptophol production, thereby activating the FTO-IGF2BP1-LGR6 signaling axis. These findings would indicate LRD as a microbiota-directed therapeutic strategy for neurobehavioral comorbidities of metabolic stress. Graphical
Video
✓ 已验证
产品关联
DOI
PubMed
高影响因子
JOURNAL OF NUTRITION
·
2026
·
IF 4.2
Xiaojian Xu,Zhenhong Yan,Yifan Hu,Haoyi Jiang,Lingling Sun,Renshuai Yi,Xianghua Yan
Background Our prior work associated Oscillibacter valericigenes and valerate-related features with offspring birth weight in Landrace × Yorkshire sows, but functional evidence was limited. Objectives To test whether O. valericigenes or valerate increases late-gestation fetal weight and characterize maternal metabolic and placental responses. Methods Pregnant mice received 200 μL of sterile culture medium (Control), O. valericigenes bacterial suspension (OV_B; 10 8 CFU/mL), or sterile-filtered culture supernatant (OV_M) by oral gavage every other day from embryonic day (E) 7.5 to E17.5 (n = 7/group). Another cohort received sodium valerate (SV; 0–1.20 mg/mL) in drinking water from E7.5 to E17.5 (n = 8/group). At E18.5, fetal and placental weights, serum hormone concentrations, colonic and serum short-chain fatty acid concentrations, and placental gene expression were measured and analyzed using one-way ANOVA followed by Dunnett’s test. Multi-omics profiling was performed in the Control and OV_B groups. Results Compared with control, maternal gavage with O. valericigenes or its culture supernatant increased fetal weight by 4.56% and 6.81%, respectively (both P < 0.01), and placental weight by 8.57% and 8.25%, respectively (both P < 0.05). Multi-omics analyses revealed that O. valericigenes gavage was associated with altered estrogen-related metabolism and placental proteomic and transcriptional responses related to nutrient transport, angiogenesis, and tight junctions. Compared with the control group, OV_B increased colonic valerate concentration by 53.64% ( P < 0.05) and tended to increase serum estradiol concentration by 34.58% ( P = 0.054). SV supplementation at 0.60 mg/mL increased fetal weight by 6.44% ( P < 0.01), placental weight by 7.30% ( P < 0.05), and serum valerate concentration by 125.25% ( P < 0.05) compared with its respective control. SV supplementation did not significantly alter serum estradiol or progesterone concentrations. Conclusions O . valericigenes increases placental and fetal weights and is associated with altered estrogen-related metabolism and colonic valerate production in mice.
✓ 已验证
DOI
高影响因子
Food & Function
·
2022
·Vol. 14
·期 2
·857-873
·
IF 6.317
Ke Lan,Huabing Yang,Junping Zheng,Haiming Hu,Tianxiang Zhu,Xiaojuan Zou,Baifei Hu,Hongtao Liu
Poria cocos, a widely accepted function food in China, has multiple pharmacological activities. This study aimed to investigate the therapeutic effect and molecular mechanism of Poria cocos oligosaccharides (PCOs) against dextran sodium sulfate (DSS)-induced mouse colitis. In this study, BALB/c mice were treated with 3% (w/v) DSS for seven days to establish a colitis model. The results showed that oral administration of PCOs (200 mg per kg per day) significantly reversed the changes in the physiological indices in colitis mice, including body weight, disease activity index scores (DAI), spleen index, and colon length. From the qRT-PCR assay, it was observed that PCOs suppressed the mRNA expression of pro-inflammatory cytokines, such as Tnf-α, Il-1β, and Il-6. In addition, PCOs protected the intestinal barrier from damage by promoting the expression of mucins and tight junction proteins at both mRNA and protein levels. Upon 16S rDNA sequencing, it was observed that PCO treatment partly reversed the changes in the gut microbiota of colitis mice by selectively regulating the abundance of specific bacteria. And Odoribacter, Muribaculum, Desulfovibrio, Oscillibacter, Escherichia–Shigella, and Turicibacter might be the critical bacteria in improving colitis via PCOs. Finally, using antibiotic mixtures to destroy the intestinal bacteria, we documented that PCO fermentation broth (PCO FB) instead of PCOs prevented the occurrence of colitis in gut microbiota-depleted mice. In conclusion, PCOs showed a protective effect on colitis by reversing gut microbiota dysbiosis. Our study sheds light on the potential application of PCOs as a prebiotic for treating colitis.
研究领域:
药理学
·
免疫学
·
微生物学
·
胃肠病学
✓ 已验证
产品关联
DOI
PubMed
高影响因子
FOOD RESEARCH INTERNATIONAL
·
2021
·
IF 6.475
Siya Wu,Jihui Zuo,Yang Cheng,Ya Zhang,Zhongshan Zhang,Mingjiang Wu,Yue Yang,Haibin Tong
Type 2 diabetes mellitus (T2DM) is considered a rapidly growing chronic disease that threatens human health worldwide. Extracts of various seaweeds have been shown to have anti-diabetic activity. Sargarsum fusiforme, an edible brown seaweed, has been shown to possess anti-inflammatory, anti-diabetic and anti-obesity activities. In this study, we investigated the beneficial effect of an ethanol extract of S. fusiforme (EE) on type 2 diabetes in mice induced with high-fat diet (HFD) and streptozotocin (STZ). Administering EE to the diabetic mice significantly reduced food intake, water intake and fasting blood glucose (FBG), while improving glucose tolerance, lipid profile and ameliorating hepatic oxidative stress. Furthermore, these animals also exhibited significantly diminished epididymal fat deposition, as well as less pathological changes in the heart and liver tissues, while displaying some highly enriched benign gut bacteria (e.g., Intestinimonas , Oscillibacter , Lachnoclostridium, unidentified_Lachnospiraceae , Roseburia and Anaerotruncus ) and a lower abundance of bacteria associated with diabetes or other metabolic diseases (e.g., Enterorhabdus and Romboutsia ). Metabolomic analysis revealed reduced levels of branched-chain amino acids (BCAA), such as l -valine and l -isoleucine, aromatic amino acids (AAA), such as l -tyrosine and l -phenylalanine, and increased levels of 4-hydroxyphenylacetic acid (4-HPA) in the gut content, suggesting that EE may impact T2DM through modulation of these compounds in the gut of the animals. Taken together, the results implied that S. fusiforme may contain valuable active components other than polysaccharides that have potential benefit in alleviating T2DM.
研究领域:
药理学
·
营养学
·
糖尿病研究
·
微生物学
·
代谢组学
✓ 已验证
产品关联
DOI
PubMed
高影响因子
危险品化学品经营许可证（带存储）